Share of Piramal Pharma Ltd is currently trading at around Rs.206/- Existing as well as prospective Investors are asking for Piramal Pharma Share Price Target 2026,2030,2035,2040. In this article, we will discuss about the business prospects and financial performance of the Company and based on our discussion and analysis will tell you the Piramal Pharma Share Price Target 2026,2030,2035,2040.
Discussion and Business & Financial Analysis of Piramal Pharma Ltd:
Piramal Pharma Ltd has strengthened its position as a diversified global pharmaceutical company, with three key businesses: Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and Consumer Healthcare. The company serves customers across major international markets and has built capabilities in specialised pharmaceutical manufacturing, hospital products and established consumer brands.
The company’s latest performance indicates a significant improvement in operating momentum. In Q1 FY27, revenue from operations increased 17% year-on-year to ₹2,270 crore, while EBITDA rose sharply by 72% to ₹285 crore. The EBITDA margin expanded to 12.5% from 8.5% in the corresponding quarter. Importantly, all three businesses delivered strong growth: CDMO revenue increased 19% to ₹1,187 crore, CHG grew 17% to ₹743 crore, and Consumer Healthcare rose 15% to ₹347 crore. However, the company continued to report a consolidated net loss of ₹69 crore, indicating that improvement in operating profitability still needs to translate into sustainable bottom-line profits.
The CDMO business remains the most important long-term growth engine. Rising demand for outsourced pharmaceutical development and manufacturing, increasing biopharma activity and supply-chain diversification provide favourable opportunities. Strong order inflows, healthy RFP activity and improving capacity utilisation could support further growth. The CHG business also has attractive prospects because of Piramal Pharma’s established presence in specialised hospital products and leadership in important anaesthesia therapies. The integration of the Kenalog portfolio provides an additional growth opportunity.
Consumer Healthcare provides another relatively stable growth pillar. The company’s power brands, wider distribution, e-commerce expansion and premiumisation are supporting demand. Continued investment in brand building could help Piramal Pharma increase its market presence in India’s growing consumer healthcare market.
Looking ahead, the company’s prospects appear positive, although not without risks. Management has indicated expectations of sustained revenue and EBITDA growth in FY27. Long-term growth will depend on successful execution of capacity expansion, new product opportunities, margin improvement and debt reduction. Piramal Pharma’s FY25 performance had already demonstrated a strong recovery, with revenue growing 12% to ₹9,151 crore and EBITDA increasing 15% to ₹1,580 crore.
Overall, Piramal Pharma appears to be entering a potentially stronger phase of its business cycle. Its diversified portfolio, global CDMO capabilities, specialised hospital products and established consumer brands provide a solid foundation for future expansion. Nevertheless, investors should monitor profitability, leverage, regulatory compliance and the pace of debt reduction. If management successfully converts strong revenue growth into consistent positive earnings and higher margins, Piramal Pharma could have attractive long-term business prospects.
Share Price Targets:
Piramal Pharma Share Price Target 2026
Based on the above discussion and analysis, the share price of Piramal Pharma Limited may touch the level of around Rs.215–225 in 2026
Piramal Pharma Share Price Target 2030
Based on the above discussion and analysis, the share price of Piramal Pharma Limited may touch the level of around Rs.425–450 in 2030
Piramal Pharma Share Price Target 2035
Based on the above discussion and analysis, the share price of Piramal Pharma Limited may touch the level of around Rs.900–1000 in 2035
Piramal Pharma Share Price Target 2040
Based on the above discussion and analysis, the share price of Piramal Pharma Limited may touch the level of around Rs.2000–2250 in 2040
Disclaimer: Investment in Capital Market/Share Prices are subject to market fluctuations and are dependent on several factors. These predictions are based on the current market conditions and the future market expectations. Investors are advised to take into consideration all these factors before making any investment in Capital Market. This article should not be treated as Investment advisory and is for general Guidance & Educational purpose only. We keep revising our share price targets based on the latest information available with us. Please keep visiting our website regularly to keep yourself updated. MoneyInsight does not offer investment advice and does not encourage any action based on its content.
Read Also:
How to make maximum profit with minimum investment from the Stock Market ? – MoneyInsight
Also Read :
How to make money from share market? (indiatimes.com)
Visit our another Group Website regularly for more such Educational Research Articles:
How to make maximum profit with minimum investment from the Stock Market ? – MoneyInsight
Visit & Subscribe our Devotional Music Channel on YouTube:
Indian Devotional Music – YouTube
Visit our Website regularly for more such Educational Research Articles:
MoneyInsight – We Provide Insight to Your Money
